The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma-Reference-Cited by-同舟云学术

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

Published:2019-05-10 Issue:8 Volume:8 Page:1608132
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Chen Hao¹,Yang Meng²,Wang Qinghua¹,Song Fengju¹,Li Xiangchun²,Chen Kexin¹

Affiliation:

1. Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

2. Tianjin Cancer Institute, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Tianjin City

Changjiang Scholars and Innovative Research Team in University in China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1608132

Reference58 articles.

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer